To determine if the change of LINC00052 expression is HER3 specific, we treated cancer cells with lapatinib (a compound that inhibits kinase activity of HER2 and EGFR) or trastuzumab (a HER2-blocking antibody). The gene discussed is ERBB2; the disease is cancer.